Armata Pharmaceuticals, Inc.

Armata Pharmaceuticals exhibits a distressed capital structure with negative total equity of $-311.6 million against total assets of $69.8 million. The balance sheet shows total liabilities of $381.4 million, resulting in a current ratio of 0.64, indicating that current liabilities exceed current assets. Cash and equivalents stand at $4.8 million, while operating cash flow is negative $5.8 million, highlighting severe liquidity constraints. The company has incurred significant operating losses since inception and relies on external financing to continue operations, raising substantial doubt about its ability to continue as a going concern.

Profitability metrics reflect the pre-commercial stage of the business, with a net income loss of $115.3 million and an operating income loss of $8.8 million in Q1 2026. Return on assets is negative 1.65, and return on equity is reported as 0.37, though this metric is distorted by the negative equity base. The company does not generate positive earnings, resulting in a negative EV/EBITDA multiple of -20.5. As a biotechnology firm, losses are expected during the development phase, but the magnitude of losses relative to the small asset base underscores the high burn rate and dependency on capital raises.

Revenue mix and geographic exposure data are not explicitly detailed in the provided financial snapshot, but the business model is centered on the development of bacteriophage-based therapies. The company focuses on disrupting biofilms and restoring sensitivity to antibiotics, targeting the global threat of antibiotic resistance. Without commercial sales, revenue concentration risk is not applicable in the traditional sense, but the entire business value is concentrated in the success of its clinical pipeline, particularly the lead candidate AP-SA02.

Growth trajectory is defined by clinical development milestones rather than revenue expansion. The company has received critical FDA guidance on the Phase 3 clinical study design for AP-SA02, which will assess superiority over the current standard of care for complicated S. aureus infections. Historical revenue data is not provided, but the company has consistently incurred operating losses and relied on equity, debt, and grant financing to fund operations. The path to growth depends on successful completion of clinical trials and regulatory approval, with no near-term revenue visibility.

Risk factors are elevated, with high liquidity risk and medium dilution risk identified. The company has disclosed going-concern language in its filings, citing the need for additional funds to continue operations. Dilution risk is present due to the potential need for equity financing, as evidenced by the recent entry into a Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC. The company also faces execution risk in manufacturing sufficient quantities of product candidates for clinical trials and securing regulatory approval.

Recent events include the filing of an 8-K with high severity material items, likely related to the Capital on Demand Sales Agreement entered into on December 1, 2025. This agreement allows the company to offer and sell shares of common stock, providing a mechanism to raise capital but introducing dilution risk. Analyst estimates show a mean price target of $17.50, with a mean recommendation of 2.00 (Buy), indicating some market optimism despite the financial challenges. The company continues to advance its clinical development plans, including Phase 1, 2, and 3 trials, while managing its cash position and financing needs.

Operating income -$8.8M.

• ▍Operating income -$8.8M

Operating income -$22.8M.

• ▍Operating income -$22.8M

Operating income -$36.6M.

• ▍Operating income -$36.6M

Operating income -$42.4M.

• ▍Operating income -$42.4M

Operating income -$42.4M.

• ▍Operating income -$42.4M

Operating income -$40.9M.

• ▍Operating income -$40.9M

Operating income -$40.9M.

• ▍Operating income -$40.9M